menu
    • menu

    Company profile for Butantan Institute

    NEW Drugs in Dev: 4
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Instituto Butantan is the main producer of immunobiological products in Brazil. As such, it is responsible for a large percentage of the domestic production of hyperimmune sera and for a great volume of the vaccine antigens made in Brazil that make up the vaccines used by the Ministry of Health's National Immunization Program, PNI. The technological development activities related to the production of health products are basica...
    Instituto Butantan is the main producer of immunobiological products in Brazil. As such, it is responsible for a large percentage of the domestic production of hyperimmune sera and for a great volume of the vaccine antigens made in Brazil that make up the vaccines used by the Ministry of Health's National Immunization Program, PNI. The technological development activities related to the production of health products are basically associated with the production of vaccines, sera and biopharmaceuticals for human use.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Butantan InstituteBrazil Flag
    Country
    Country
    Brazil
    Address
    Address
    Av. Vital Brasil, 1500 - Butantã 05503-900 São Paulo, SP
    Telephone
    Telephone
    +55 (11) 2627-9300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://butantan.gov.br/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IASO Bio Forms Global Partnership With Instituto Butantan
    IASO Bio Forms Global Partnership With Instituto Butantan

    10 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iaso-bio-establishes-international-partnership-with-instituto-butantan-to-develop-innovative-therapy-for-hematological-cancer-302739305.html

    PR NEWSWIRE
    10 Apr 2026
    Share Share
    Butantan, Replicate Develop srRNA Rabies Vaccine in Latin America
    Butantan, Replicate Develop srRNA Rabies Vaccine in Latin America

    04 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/replicate-bioscience-and-instituto-butantan-enter-collaborative-agreement-to-develop-and-commercialize-replicates-self-replicating-rna-srrna-rabies-vaccine-in-latin-america-302631083.html

    PR NEWSWIRE
    04 Dec 2025
    Share Share
    Sinovac COVID-19 Vaccine Collab with Butantan Receives Approval Ph III Trial
    Sinovac COVID-19 Vaccine Collab with Butantan Receives Approval Ph III Trial

    06 Jul 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200706005305/en

    BUSINESSWIRE
    06 Jul 2020
    Share Share
    Sinovac and Butantan Join Efforts to Advance the Clinical Development
    Sinovac and Butantan Join Efforts to Advance the Clinical Development

    10 Jun 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200611005491/en

    BUSINESSWIRE
    10 Jun 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search